Magnus interviewed for feature article in the Davos edition of The Innovator.
"Corporations in just about every industry are struggling with how to innovate. Culture clash with startups, a not-invented-here attitude and fear of anything that might change traditional business models and impact quarterly results are some of the reasons why large, incumbent firms rarely introduce radical product innovations.
The phenomenon is sometimes referred to as “the incumbent’s curse.” And the pharmaceutical industry, and life science in general, face additional challenges due to complex and uncertain development processes, regulatory issues, long lead times, large investments, huge financial risks, and high failure rates."
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.
You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.
I have read this warning and will not be using any of the contained product information for clinical purposes.